Analyst Research Report Snapshot

Title:

BTG - REVISING PROSTATE PROJECTIONS

Price:

$10.00

Provider:

Edison Investment Research

Date:

24 Jul 2013

Pages:

8

Type:

AcrobatPDF

Companies referenced:

BTG.L

Available for Immediate Download
Summary:

BTG is both a beneficiary (Zytiga sales growth) and casualty (brachytherapy sales decline) of the changing treatment landscape for metastatic prostate cancer (mCRPC). However, increased Zytiga royalty projections more than offset the impact of brachytherapy discontinuation in our financial model. Our FY14 revenue and operating profit rises by 1-2%, while our fair value increases to £1.86bn or 516p per share.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.